Stress Reduction to Reduce Risk for Arrhythmia in ICD Patients (The RISTA Study) (RISTA)
|ClinicalTrials.gov Identifier: NCT00627263|
Recruitment Status : Completed
First Posted : March 3, 2008
Last Update Posted : January 17, 2018
|Condition or disease||Intervention/treatment|
|Arrhythmias, Cardiac||Behavioral: Stress reduction treatment (SRT) program|
An ICD is a device designed to quickly detect a life-threatening, rapid heartbeat. Through a process called defibrillation, the ICD tries to convert an abnormal heart rhythm back to normal by delivering an electrical shock to the heart. The ICD continuously monitors heartbeats to ensure that they are normal, and it only delivers a shock to the heart when it senses a life-threatening arrhythmia. Because of the recent funding approval by Medicaid, it is now estimated that more than 500,000 people will receive ICDs annually. Although ICDs are life-saving medical devices, some people may experience anxiety, depression, and impaired quality of life as a result of the repeated ICD shocks. Additionally, increased mental and emotional stress and anger may increase the likelihood of experiencing more arrhythmias requiring an ICD shock. SRT programs that encourage people to manage their emotions may decrease the frequency of arrhythmias. Furthermore, SRT programs have been shown to be successful at reducing other stress-related heart conditions. The purpose of this study is to evaluate the effectiveness of an SRT program at reducing the incidence of ICD shock-treated arrhythmias among people with newly implanted ICDs.
This study will enroll people who have recently received an ICD. Initially, participants will complete questionnaires about mood and attitudes. Next, at a baseline study visit, participants will complete a mental stress exercise in which they will perform math problems and describe an experience that made them angry. During this exercise, participants will undergo blood pressure measurements, blood collection, and an electrocardiogram (EKG) to measure electrical activity of the heart. Participants will also wear a monitor for 24 hours after the study visit to record heart activity. Participants will then be randomly assigned to either take part in the SRT group and receive usual care or only receive usual care. For 10 weeks, participants in the SRT group will attend 8 group sessions that will focus on learning and applying stress reduction techniques to everyday living. All participants will attend a 3-month follow-up visit for repeat baseline testing. At Months 6, 12, and 24, participants will complete questionnaires during routine doctor's visits or by mail.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||314 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Single (Outcomes Assessor)|
|Official Title:||Reducing Vulnerability to ICD Shock Treated Ventricular Arrhythmias|
|Actual Study Start Date :||January 2008|
|Primary Completion Date :||December 2012|
|Study Completion Date :||December 2012|
No Intervention: 1
Participants will receive the usual cardiologic care for ICD patients provided by their medical team.
In addition to the usual cardiologic care for ICD patients provided by the participants medical team, those randomized to Intervention will receive the stress reduction treatment (SRT) program (see below).
Behavioral: Stress reduction treatment (SRT) program
The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
- ICD shock-treated ventricular arrhythmia event-free survival [ Time Frame: Measured at Month 24 ]The occurrence of ICD shock treated ventricular arrhythmia
- Laboratory stress-provoked arrhythmogenic changes in the heart rhythm [ Time Frame: Measured at Baseline and Month 6 ]Arrhythmogenic changes in the heart rhythm during laboratory mental stress
- 24-hour heart rate variability [ Time Frame: Measured at Baseline and Month 6 ]Heart rate variability on 24 hour holter monitoring
- Quality of life [ Time Frame: Measured at Month 24 ]SF-36 assessment
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00627263
|United States, Connecticut|
|Yale University Medical School|
|New Haven, Connecticut, United States, 06520|
|Principal Investigator:||Matthew M. Burg, PhD||Yale University|